+91-98 455 710 46 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Tag

lupin gavis deal

Lupin to divest two Gavis drugs for deal approval

Posted on22 Feb 2016

TagsGavis, Lupin, lupin gavis deal, lupin to acquire gavis

Comments0

India’s Lupin Ltd will divest two generic drugs sold by Gavis Pharmaceuticals LLC to clear antitrust hurdles related to its $880 million...

Lupin to acquire Gavis Pharma for for $880 mn

Posted on24 Jul 2015

TagsGavis, Lupin, lupin gavis deal, lupin to acquire gavis, Lupin to acquire Gavis Pharma for for $880 mn, Lupin's acquisition, Why Lupin acquire gavis

Comments0

Lupin, India based pharmaceutical company, will acquire Gavis Pharmaceuticals for Rs 5,610 crore (for $880 mn). Why this acquisition? The acquisition will...

Our Popular Courses

Pharma Product Management
Digital Pharma Marketing
Strategic Management
Regulatory Affairs
Pharma Marketing
European DRA
Sales Management
Pharmacovigilance
Production Management
ASEAN DRA
GCC DRA
Pharma Project Management
Export Documentation

Recent Articles

What is the meaning of pharmaceutical profiling?
What is phase zero study? What it’s significance?
Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
Covishield received emergency use authorization in India
Glenmark introducing Remogliflozin + Vildagliptin combination first time in India
Myovant and Pfizer’s $4.2 Billion Deal for Orgovyx
Insight on Aurobindo and COVAXX exclusive licensing agreement
Pfizer, BioNTech covid vaccine approval tilldate
Chugai received MHLW, Japan marketing authorization for humanized anti-PD-L1 monoclonal antibody, Tecentriq to treat unresectable advanced/recurrent NSCLC
Lynparza received marketing authorization by MHLW, Japan to treat advanced ovarian, prostate and pancreatic cancers
AstraZeneca – Alexion $39 billion deal
UK approves Pfizer-BioNTech’s COVID-19 vaccine. Rollout in week time
Saudi Arabia signs non-binding vaccine agreement with CureVac
Telix Pharma to acquire TheraPharm GmbH
Case Study: Clinical basis of MHLW approval of Astellas’s Evrenzo to treat anemia of CKD in adult patients not on dialysis
Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development
PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
Pfizer submitted application for emergency use of Covid vaccine
Take Self Competency Test in Esxport Documentation

Course Category

KPE® – Certificate Program (1 Month)
KPE® – Certificate Program (1 Week)
KPE® – Publications / White Papers / Workshop / Others
KPE® Advance Diploma Program (1 Year Program)
KPE® Advance Diploma Program – Dual Specialization (1 Year Program)
KPE® Executive Program (1 Year Program)

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query

First Name

Last Name

Email Address

Your Query *

Write Here

7 plus 7 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.